Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZL-6201 · 1 trial · 2 indications
Number of subjects with dose limiting toxicities (DLTs) through dose escalation only.
Number of subjects with treatment-emergent adverse effects through dose escalation and expansion.
Number of subjects with Serious Adverse Events through dose escalation and expansion.
Vitals will be measured in Riva Rocci (RR) in mmHG and Pulse in beats per minute
ECG will be measured in ECG intervals (QT and QTc with Fridericia correction, and PR), QRS duration, and heart rate will be tested and analyzed.
| Arm | Type | Description |
|---|---|---|
| ZL-6201 | EXPERIMENTAL | ZL-6201 as a single agent |
| Name | Type | Description |
|---|---|---|
| ZL-6201 | DRUG | ZL-6201 as a single-agent |
Inclusion Criteria: * Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \> 3 months * Participants must have histologically confirmed and documented diagnosis of locally advanced u...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ZL-6201 is an investigational small molecule being developed for the treatment of solid tumors, including sarcomas. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ZL-6201 targets LRRC15, a protein involved in the tumor microenvironment. By binding to this target, the drug aims to modulate the tumor's surrounding cells, potentially inhibiting tumor growth and progression.
ZL-6201 is being developed by Zai Lab Limited, a biopharmaceutical company. The company is conducting clinical trials for this drug in the United States and China.
ZL-6201 is in Phase 1 clinical development. It is currently being studied in a Phase 1a/b trial that is recruiting participants, and it remains an investigational drug not yet approved for commercial use.
ZL-6201 is being evaluated in a Phase 1a/b study (NCT07374848) that assesses its safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors and sarcomas. The trial is recruiting up to 180 participants aged 18 years and older.